We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$4.49B
AUM Growth
+$287M
Cap. Flow
+$321M
Cap. Flow %
7.16%
Top 10 Hldgs %
50.53%
Holding
128
New
23
Increased
12
Reduced
25
Closed
8

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$173M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$75.9M
3
NVAX icon
Novavax
NVAX
+$49.8M
4
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$43.3M
5
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$42.5M

Top Sells

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$71.6M
2
VIE
Viela Bio, Inc. Common Stock
VIE
+$51.4M
3
IMVT icon
Immunovant
IMVT
+$32.3M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$30.6M
5
KURA icon
Kura Oncology
KURA
+$21.2M

Sector Composition

Rank Sector Weight
1 Healthcare 77.01%
2 Miscellaneous 22.76%
3 Financials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$76.5B
$442M 9.84%
2,000,000
+1,500,000
+300% +$328M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
$396M 8.83%
1,000,000
+500,000
+100% +$193M
AVIR icon
3
Atea Pharmaceuticals
AVIR
$413M
$396M 8.82%
6,411,355
– –
TPTX
4
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$260M 5.8%
2,750,000
+357,703
+15% +$42.5M
DSGN icon
5
Design Therapeutics
DSGN
$783M
$146M 3.26%
+5,114,850
New +$173M
XBI icon
6
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$136M 3.02%
1,000,000
-500,000
-33% -$74.9M
BBIO icon
7
BridgeBio Pharma
BBIO
$13.4B
$134M 2.98%
2,168,909
-96,853
-4% -$6.34M
FMTX
8
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$132M 2.95%
4,720,000
+260,000
+6% +$9.38M
RVMD icon
9
Revolution Medicines
RVMD
$42B
$116M 2.58%
2,525,000
+29,934
+1% +$1.34M
BCAB
10
DELISTED
BIOATLA INC
BCAB
$110M 2.45%
43,841
-2,000
-4% -$5.13M
OLMA icon
11
Olema Pharmaceuticals
OLMA
$851M
$105M 2.34%
3,195,544
– –
CCCC icon
12
C4 Therapeutics
CCCC
$424M
$92.1M 2.05%
2,490,065
– –
APLS
13
DELISTED
Apellis Pharmaceuticals
APLS
$80.1M 1.78%
1,866,108
– –
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.93B
$74.3M 1.66%
+2,340,914
New +$75.9M
ALXO icon
15
ALX Oncology
ALXO
$243M
$65M 1.45%
881,770
– –
ZYME icon
16
Zymeworks
ZYME
$1.88B
$63.2M 1.41%
2,000,000
+800,000
+67% +$32.5M
RCKT icon
17
Rocket Pharmaceuticals
RCKT
$382M
$60.7M 1.35%
1,368,550
– –
OMER icon
18
Omeros
OMER
$1.26B
$58.7M 1.31%
3,300,030
-699,970
-17% -$13.6M
STOK icon
19
Stoke Therapeutics
STOK
$1.8B
$55.8M 1.24%
1,437,807
– –
TARS icon
20
Tarsus Pharmaceuticals
TARS
$3.63B
$55.3M 1.23%
1,714,269
– –
RNAM
21
DELISTED
Avidity Biosciences
RNAM
$53.8M 1.2%
2,464,545
-2
-0% -$49
ACRS icon
22
Aclaris Therapeutics
ACRS
$783M
$50.4M 1.12%
+2,000,000
New +$39.1M
MRTX
23
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$47.1M 1.05%
275,000
-50,000
-15% -$9.9M
NVAX icon
24
Novavax
NVAX
$1.54B
$45.3M 1.01%
+250,000
New +$49.8M
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
$43.6M 0.97%
850,000
-350,000
-29% -$21.1M
1
2 3 4 5

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q1 2021 Portfolio in Review

As of Q1 2021, Cormorant Asset Management held 128 positions worth $4.49B, up 6.8% from $4.2B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Cormorant Asset Management deployed $321M of net new capital in Q1 2021, opening 23 new positions and adding to 12 existing holdings. Its largest new stake was Design Therapeutics: 5,114,850 shares worth $146M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 81% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Beam Therapeutics, an estimated $71.6M trimmed.

  • Cormorant Asset Management's largest Q1 2021 buy was Design Therapeutics: 5,114,850 shares worth $146M.
  • Cormorant Asset Management added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2021, an estimated $42.5M increase.
  • Cormorant Asset Management's biggest Q1 2021 reduction was Beam Therapeutics, cutting an estimated $71.6M.
  • Cormorant Asset Management fully exited Viela Bio, Inc. Common Stock in Q1 2021, selling an estimated $51.4M.
  • Cormorant Asset Management's ten largest holdings make up 51% of its $4.49B portfolio in Q1 2021.
  • Cormorant Asset Management opened 23 new positions and closed 8 in Q1 2021.
  • Cormorant Asset Management's portfolio value rose 6.8% quarter-over-quarter to $4.49B.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.